Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressing and invariably fatal neurodegenerative disorder that is gaining global awareness. Due to clinical data interpretation and slightly differing regulatory sentiments, there is an inequity in access to approved ALS treatments across the world. Clinical trials are, therefore, an essential part of pharmacotherapy for people living with ALS (plwALS). Despite research advancements, access to clinical trials is limited, with a reported 5-10% of plwALS participating in clinical trials.
Read our article, which explores factors impacting trial participation and considerations when seeking to reach and enroll qualified participants.
